Erythema multiforme
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
EM minor
topical emollient
Typical targets or raised edematous papules, with acral distribution, without involvement of mucosal sites, and involving <10% total body surface area.
Topical emollients should be applied to all lesions to hydrate the skin and also act as a protective barrier.
topical or oral corticosteroids
Treatment recommended for ALL patients in selected patient group
Topical or systemic corticosteroids can be used to reduce inflammation and speed resolution.
In EM minor, topical corticosteroids have been shown to benefit clearance of lesions.[1]Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018 Feb;54(1):177-84. http://www.ncbi.nlm.nih.gov/pubmed/29352387?tool=bestpractice.com
Primary options
triamcinolone topical: (0.1%) apply to the affected area(s) twice daily
OR
clobetasol topical: (0.05%) apply to the affected area(s) twice daily
Secondary options
prednisone: 40-60 mg orally once daily for 5-10 days
withdrawal of suspected causative drug
Treatment recommended for SOME patients in selected patient group
Review of drug exposure is necessary for all patients with EM. If EM is suspected to be drug-induced, withdrawal of the suspected causative drug is essential.
Drugs that have been associated with EM include certain antibiotics; docetaxel or paclitaxel; immune checkpoint inhibitors; sorafenib; tumor necrosis factor (TNF)-alpha inhibitors; antimalarials; hydroxychloroquine; lenalidomide; methotrexate; anticonvulsants; statins; bisphosphonates; nonsteroidal anti-inflammatory drugs (NSAIDs); metamizole; oral contraceptives; imiquimod; lidocaine; triclocarban; barium contrast.[1]Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018 Feb;54(1):177-84. http://www.ncbi.nlm.nih.gov/pubmed/29352387?tool=bestpractice.com [18]Borrás-Blasco J, Navarro-Ruiz A, Borrás C, et al. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009 Nov;102(11):1133-40. http://www.ncbi.nlm.nih.gov/pubmed/19864977?tool=bestpractice.com [19]Lenalidomide: Stevens-Johnson syndrome. Prescrire Int. 2010 Jun;19(107):125. http://www.ncbi.nlm.nih.gov/pubmed/20740722?tool=bestpractice.com [20]Ballester I, Guijarro J, Silvestre JF, et al. Erythema multiforme induced by imiquimod 5% cream. Int J Dermatol. 2014 Jul;53(7):e347-8. http://www.ncbi.nlm.nih.gov/pubmed/24602041?tool=bestpractice.com [21]Sai Keerthana PC, Anila KN, Reshma R. Naproxen induced erythema multiforme - a rare case report. Int J Pharm and Pharmaceutical Sci. 2017;9:294-5. https://innovareacademics.in/journals/index.php/ijpps/article/viewFile/14903/9961 [22]Rodríguez-Pazos L, Sánchez-Aguilar D, Rodríguez-Granados MT, et al. Erythema multiforme photoinduced by statins. Photodermatol Photoimmunol Photomed. 2010 Aug;26(4):216-8. http://www.ncbi.nlm.nih.gov/pubmed/20626826?tool=bestpractice.com [23]Rodríguez-Pazos L, Gómez-Bernal S, Rodríguez-Granados MT, et al. Photodistributed erythema multiforme. Actas Dermosifiliogr. 2013 Oct;104(8):645-53. https://www.actasdermo.org/en-photodistributed-erythema-multiforme-articulo-S1578219013001728 http://www.ncbi.nlm.nih.gov/pubmed/23962583?tool=bestpractice.com [24]Utsunomiya A, Oyama N, Iino S, et al. A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and/or complementary immunomodulatory effects. Case Rep Dermatol. 2018 Jan 18;10(1):1-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836162 http://www.ncbi.nlm.nih.gov/pubmed/29515387?tool=bestpractice.com [25]de Arruda JA, Silva P, Amaral MB, et al. Erythema multiforme induced by alendronate sodium in a geriatric patient: a case report and review of the literature. J Clin Exp Dent. 2017 Jul;9(7):e929-33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549594 http://www.ncbi.nlm.nih.gov/pubmed/28828163?tool=bestpractice.com [26]Abou Assalie N, Durcan R, Durcan L, et al. Hydroxychloroquine-induced erythema multiforme. J Clin Rheumatol. 2017 Mar;23(2):127-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321779 [27]Mantovani A, Álvares-Da-Silva MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report. Ann Hepatol. 2019 Sep-Oct;18(5):777-9. https://www.sciencedirect.com/science/article/pii/S1665268119300997 http://www.ncbi.nlm.nih.gov/pubmed/31085038?tool=bestpractice.com However, this list is not exhaustive and you should check your local drug information source.
sterile dressings
Treatment recommended for ALL patients in selected patient group
If any lesions are open, they should be gently cleaned and covered with sterile dressings to prevent secondary bacterial infection.
oral analgesia
Treatment recommended for ALL patients in selected patient group
Analgesics (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs]) can be taken for general pain and discomfort caused by the lesions.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
and/or
ibuprofen: 200-400 mg orally every 6-8 hours when required, maximum 2400 mg/day
oral antiviral therapy
Treatment recommended for SOME patients in selected patient group
Oral antivirals are used for cases of oral herpes simplex virus (cold sores) and genital herpes. Dose depends on indication. See Herpes simplex virus infection (Treatment algorithm).
Primary options
acyclovir: herpes labialis: 200 mg orally five times daily for 5 days; genital herpes (initial episode): 400 mg orally three times daily for 7-10 days; genital herpes (recurrence): 800 mg orally twice daily for 5 days, or 400 mg three times daily for 5 days, or 800 mg orally three times daily for 2 days
OR
valacyclovir: herpes labialis: 2000 mg orally twice daily for 1 day; genital herpes (initial episode): 1000 mg orally twice daily for 7-10 days; genital herpes (recurrence): 500 mg orally twice daily for 3 days, or 1000 mg once daily for 5 days
OR
famciclovir: herpes labialis: 1500 mg orally once daily for 1 day; genital herpes (initial episode): 1000 mg orally once daily for 1 day; genital herpes (recurrence): 125 mg orally twice daily for 5 days, or 1000 mg twice daily for 1 day
macrolide or doxycycline
Treatment recommended for SOME patients in selected patient group
Guidelines on the treatment of atypical pneumonia recommend empiric use of a macrolide or doxycycline for uncomplicated community-acquired pneumonia to ensure coverage of atypical organisms.[47]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67. https://www.atsjournals.org/doi/10.1164/rccm.201908-1581ST http://www.ncbi.nlm.nih.gov/pubmed/31573350?tool=bestpractice.com See Mycoplasma pneumoniae infection (Treatment algorithm).
Primary options
azithromycin: 500 mg orally once daily on the first day, followed by 250 mg once daily for 4 days; 500 mg intravenously once daily for 7-10 days
OR
clarithromycin: 500 mg orally every 12 hours for 14-21 days
OR
erythromycin base: 500 mg orally every 6 hours for 14-21 days; 1000 mg intravenously every 6 hours for 14-21 days
OR
doxycycline: 100 mg orally every 12 hours for 14 days
EM major
topical emollient
Typical targets or raised edematous papules, with acral distribution, plus involvement of 1 or more mucosal sites, and involving <10% total body surface area.
Topical emollients should be applied to all lesions to hydrate the skin and to act as a protective barrier.
oral or intravenous corticosteroids
Treatment recommended for ALL patients in selected patient group
Oral corticosteroids can be used to reduce inflammation.
In hospitalized patients, intravenous corticosteroids may be required. Careful prevention or treatment of secondary bacterial infections is necessary.
Primary options
prednisone: 40-60 mg orally once daily for 5-10 days
Secondary options
methylprednisolone sodium succinate: 1 mg/kg intravenously every 8 hours
withdrawal of suspected causative drug
Treatment recommended for SOME patients in selected patient group
Review of drug exposure is necessary for all patients with EM. If EM is suspected to be drug-induced, withdrawal of the suspected causative drug is essential.
Drugs that have been associated with EM include certain antibiotics; docetaxel or paclitaxel; immune checkpoint inhibitors; sorafenib; tumor necrosis factor (TNF)-alpha inhibitors; antimalarials; hydroxychloroquine; lenalidomide; methotrexate; anticonvulsants; statins; bisphosphonates; nonsteroidal anti-inflammatory drugs (NSAIDs); metamizole; oral contraceptives; imiquimod; lidocaine; triclocarban; barium contrast.[1]Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on erythema multiforme. Clin Rev Allergy Immunol. 2018 Feb;54(1):177-84. http://www.ncbi.nlm.nih.gov/pubmed/29352387?tool=bestpractice.com [18]Borrás-Blasco J, Navarro-Ruiz A, Borrás C, et al. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009 Nov;102(11):1133-40. http://www.ncbi.nlm.nih.gov/pubmed/19864977?tool=bestpractice.com [19]Lenalidomide: Stevens-Johnson syndrome. Prescrire Int. 2010 Jun;19(107):125. http://www.ncbi.nlm.nih.gov/pubmed/20740722?tool=bestpractice.com [20]Ballester I, Guijarro J, Silvestre JF, et al. Erythema multiforme induced by imiquimod 5% cream. Int J Dermatol. 2014 Jul;53(7):e347-8. http://www.ncbi.nlm.nih.gov/pubmed/24602041?tool=bestpractice.com [21]Sai Keerthana PC, Anila KN, Reshma R. Naproxen induced erythema multiforme - a rare case report. Int J Pharm and Pharmaceutical Sci. 2017;9:294-5. https://innovareacademics.in/journals/index.php/ijpps/article/viewFile/14903/9961 [22]Rodríguez-Pazos L, Sánchez-Aguilar D, Rodríguez-Granados MT, et al. Erythema multiforme photoinduced by statins. Photodermatol Photoimmunol Photomed. 2010 Aug;26(4):216-8. http://www.ncbi.nlm.nih.gov/pubmed/20626826?tool=bestpractice.com [23]Rodríguez-Pazos L, Gómez-Bernal S, Rodríguez-Granados MT, et al. Photodistributed erythema multiforme. Actas Dermosifiliogr. 2013 Oct;104(8):645-53. https://www.actasdermo.org/en-photodistributed-erythema-multiforme-articulo-S1578219013001728 http://www.ncbi.nlm.nih.gov/pubmed/23962583?tool=bestpractice.com [24]Utsunomiya A, Oyama N, Iino S, et al. A case of erythema multiforme major developed after sequential use of two immune checkpoint inhibitors, nivolumab and ipilimumab, for advanced melanoma: possible implication of synergistic and/or complementary immunomodulatory effects. Case Rep Dermatol. 2018 Jan 18;10(1):1-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836162 http://www.ncbi.nlm.nih.gov/pubmed/29515387?tool=bestpractice.com [25]de Arruda JA, Silva P, Amaral MB, et al. Erythema multiforme induced by alendronate sodium in a geriatric patient: a case report and review of the literature. J Clin Exp Dent. 2017 Jul;9(7):e929-33. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549594 http://www.ncbi.nlm.nih.gov/pubmed/28828163?tool=bestpractice.com [26]Abou Assalie N, Durcan R, Durcan L, et al. Hydroxychloroquine-induced erythema multiforme. J Clin Rheumatol. 2017 Mar;23(2):127-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321779 [27]Mantovani A, Álvares-Da-Silva MR. Anaphylaxis preceded by erythema multiforme with sorafenib: first case report. Ann Hepatol. 2019 Sep-Oct;18(5):777-9. https://www.sciencedirect.com/science/article/pii/S1665268119300997 http://www.ncbi.nlm.nih.gov/pubmed/31085038?tool=bestpractice.com However, this list is not exhaustive and you should check your local drug information source.
sterile dressings
Treatment recommended for ALL patients in selected patient group
If any lesions are open, they should be gently cleaned and covered with sterile dressings to prevent secondary bacterial infection.
oral analgesia
Treatment recommended for ALL patients in selected patient group
Analgesics (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs]) can be taken for general pain and discomfort caused by the lesions.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
and/or
ibuprofen: 200-400 mg orally every 6-8 hours when required, maximum 2400 mg/day
topical lidocaine and mouthwash
Treatment recommended for ALL patients in selected patient group
Magic mouthwash is the name for a mouthwash containing a number of possible formulations. A formulation recommended for symptomatic relief of painful oral lesions would contain local anesthetic (lidocaine), an antihistamine (diphenhydramine), and an antacid. It is compounded by a pharmacist.
Primary options
lidocaine oropharyngeal viscous solution: (2%) 15 mL every 3 hours when required (swish around in mouth and spit out), maximum 8 doses/day
intravenous fluids
Treatment recommended for ALL patients in selected patient group
Patients may become volume depleted due to painful oral lesions restricting fluid intake.
catheterization
Treatment recommended for ALL patients in selected patient group
The urethra may become blocked due to sloughing.
antivirals
Treatment recommended for SOME patients in selected patient group
Oral antivirals are used for cases of oral herpes simplex virus (cold sores) and genital herpes. Dose depends on indication. See Herpes simplex virus infection (Treatment algorithm).
Primary options
acyclovir: herpes labialis: 200 mg orally five times daily for 5 days; genital herpes (initial episode): 400 mg orally three times daily for 7-10 days; genital herpes (recurrence): 800 mg orally twice daily for 5 days, or 400 mg three times daily for 5 days, or 800 mg orally three times daily for 2 days
OR
valacyclovir: herpes labialis: 2000 mg orally twice daily for 1 day; genital herpes (initial episode): 1000 mg orally twice daily for 7-10 days; genital herpes (recurrence): 500 mg orally twice daily for 3 days, or 1000 mg once daily for 5 days
OR
famciclovir: herpes labialis: 1500 mg orally once daily for 1 day; genital herpes (initial episode): 1000 mg orally once daily for 1 day; genital herpes (recurrence): 125 mg orally twice daily for 5 days, or 1000 mg twice daily for 1 day
macrolide or doxycycline
Treatment recommended for SOME patients in selected patient group
Guidelines on the treatment of atypical pneumonia recommend empiric use of a macrolide or doxycycline for uncomplicated community-acquired pneumonia to ensure coverage of atypical organisms.[47]Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67. https://www.atsjournals.org/doi/10.1164/rccm.201908-1581ST http://www.ncbi.nlm.nih.gov/pubmed/31573350?tool=bestpractice.com See Mycoplasma pneumoniae infection (Treatment algorithm).
Primary options
azithromycin: 500 mg orally once daily on the first day, followed by 250 mg once daily for 4 days; 500 mg intravenously once daily for 7-10 days
OR
clarithromycin: 500 mg orally every 12 hours for 14-21 days
OR
erythromycin base: 500 mg orally every 6 hours for 14-21 days; 1000 mg intravenously every 6 hours for 14-21 days
OR
doxycycline: 100 mg orally every 12 hours for 14 days
recurrent EM
suppressive antiviral therapy
Intended for prevention of recurrences in patients with recurrent illness. If the immediate dose of valacyclovir taken at first sign of oral herpes simplex infection does not control symptoms, then valacyclovir may need to be continued for at least 6 months.
Doubling the dose may be required to control recurrences.[41]Soares A, Sokumbi O. Recent updates in the treatment of erythema multiforme. Medicina (Kaunas). 2021 Sep 1;57(9):921. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467974 http://www.ncbi.nlm.nih.gov/pubmed/34577844?tool=bestpractice.com
Acyclovir is used for patients who need liquid medications.
Primary options
valacyclovir: 1000 mg orally once daily for 6 months, or 500 mg orally twice daily for 6 months
Secondary options
acyclovir: 400 mg orally twice daily for 6 months
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer